Ariadna Tibau

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 6

Top Topics

Drug Administration

Placebo Controlled

Metastatic Breast Cancer

Top Venues

BMJ (Clinical research ed.)

Therapeutic advances in medical oncology

JCO oncology practice

This page only lists publications with an associated author ORCID identifier.

Publications

Ariadna Tibau, Thomas J Hwang, Jerry Avorn, Aaron S Kesselheim
Clinical value of guideline recommended molecular targets and genome targeted cancer therapies: cross sectional study. BMJ (Clinical research ed.) 386 (2024)
Ariadna Tibau, Thomas J Hwang, Jerry Avorn, Aaron S Kesselheim
Clinical value of guideline recommended molecular targets and genome targeted cancer therapies: cross sectional study. BMJ (Clinical research ed.) 386 (2024)
Ariadna Tibau, Thomas J Hwang, Jerry Avorn, Aaron S Kesselheim
Clinical value of guideline recommended molecular targets and genome targeted cancer therapies: cross sectional study. BMJ (Clinical research ed.) 386 (2024)
Ariadna Tibau, M Teresa Martínez, Manuel Ramos, Luis De La Cruz-Merino, Ana Santaballa, Miriam O'Connor, Noelia Martínez-Jañez, Fernando Moreno, Isaura Fernández, Juan Antonio Virizuela, Jesús Alarcón, Juan de La Haba-Rodríguez, Pedro Sánchez-Rovira, Cinta Rosa Albacar, Coralia Bueno Muiño, Catherine Kelly, Maribel Casas, Susana Bezares, Libertad Rosell, Joan Albanell
Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial. Therapeutic advances in medical oncology 15 (2023)
Ariadna Tibau, M Teresa Martínez, Manuel Ramos, Luis De La Cruz-Merino, Ana Santaballa, Miriam O'Connor, Noelia Martínez-Jañez, Fernando Moreno, Isaura Fernández, Juan Antonio Virizuela, Jesús Alarcón, Juan de La Haba-Rodríguez, Pedro Sánchez-Rovira, Cinta Rosa Albacar, Coralia Bueno Muiño, Catherine Kelly, Maribel Casas, Susana Bezares, Libertad Rosell, Joan Albanell
Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial. Therapeutic advances in medical oncology 15 (2023)
Thomas J Hwang, Aaron S Kesselheim, Ariadna Tibau, ChangWon C Lee, Kerstin N Vokinger
Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia. JCO oncology practice 18 (9) (2022)